Latest Commercialisation Strategy News

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.

First Graphene has secured advanced graphene coatings technology through the AU$250,000 acquisition of Ionic Industries and Imagine Intelligent Materials, gaining immediate entry into lucrative geotextile and environmental infrastructure sectors.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

InFocus Group Holdings has launched Codexa, a proprietary sweepstakes casino platform targeting the US market, and secured an expanded contract for its Prodigy9 subsidiary in Thailand, while navigating cash flow pressures amid ongoing R&D investment.

Dreadnought Resources has obtained regulatory approval for open pit mining at its Star of Mangaroon gold project in Western Australia, advancing its strategy to become a self-funded explorer by outsourcing development and processing.

Green360 Technologies has produced its first commercial batch of Eco-Clay under a tolling deal with Calix, advancing its low-carbon cement alternative towards market entry in Victoria by mid-2026.

Calix Limited has secured an initial A$5.7 million payment following the completion of its lithium Mid-Stream Project restructure with PLS Group, releasing $11.4 million in capital and shifting to a capital-light licensing model.

Proteomics International Laboratories has slashed a quarter of its workforce and appointed a new CFO amid a strategic pivot to commercial diagnostics, aiming to save over $1 million annually and sharpen execution.

InFocus Group Holdings Limited (ASX: IFG) has unveiled a global technical preview of Codexa, its proprietary sweepstakes casino platform, marking a key step towards commercial operations in the US market. The platform features advanced technology including blockchain fairness verification and AI-driven personalisation.